Author

Yingjia Yao

Northeastern University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 2 Assay:CRISPR screen· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Fei TengiD· 4 shared Shixin MaiD· 4 shared Zexu LiiD· 4 shared Zihan LiiD· 4 shared Chunge ZhongiD· 2 shared Han ZhangiD· 2 shared Lumen ChaoiD· 2 shared Xiaolong ChengiD· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMolecular Biology

Fei TengORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A comprehensive benchmark for multiple highly efficient base editors with broad targeting scope

Xiao‐Feng Wang, Xiaolong Cheng, Zexu Li, Shixin Ma, Han Zhang, Zhisong Chen, Yingjia Yao, Zihan Li, Chunge Zhong, You Li, Yunhan Zhang, Vipin K. Menon, Lumen Chao, Wei Li, Fei Teng

The paper benchmarks multiple base editors and develops a model to predict editing efficiency, validating edits for disease-associated variants and identifying cancer-related SNVs.

bioRxiv · Dec 17, 2024 · PreprintMolecular Biology

CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

Chunge Zhong, Wenjie Jiang, Yingjia Yao, Zexu Li, You Li, Shengnan Wang, Xiaofeng Wang, Wenjuan Zhu, Siqi Wu, Jing Wang, Shuangshuang Fan, Shixin Ma, Yeshu Liu, Han Zhang, Wenchang Zhao, , Fei Teng

This study identifies convergent therapeutic targets for chemoresistance in cancer using CRISPR screens across multiple drug conditions and cancer models.

Nature Communications · Jun 29, 2024Peer-reviewedCancer Biology

Intrinsic RNA targeting constrains the utility of CRISPR-Cas13 systems

Zexu Li, Zihan Li, Xiaolong Cheng, Xiaofeng Wang, Shixin Ma, Shengnan Wang, Zhiyan Lu, Han Zhang, Wenchang Zhao, Zhisong Chen, Yingjia Yao, Lumen Chao, Wei Li, Fei Teng

The paper evaluates CRISPR-Cas13 systems and finds that they have intrinsic RNA targets in mammalian cells, which can affect lentiviral particle production and limit their utility.

bioRxiv · May 14, 2022 · PreprintMolecular Biology

A Chemical-Enhanced System for CRISPR-Based Nucleic Acid Detection

Zihan Li, Wenchang Zhao, Shixin Ma, Zexu Li, Yingjia Yao, Fei Teng

This paper introduces CECRID, a CRISPR-based detection system enhanced with L-proline to improve sensitivity and robustness for nucleic acid detection, particularly for SARS-CoV-2.

Biosensors and Bioelectronics · Jul 9, 2021Peer-reviewedMolecular Biology